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D espite the high prevalence and impact of dental caries among adults, prevention research has focused primarily on children (Griffin et al., 2005) , and strategies to prevent adult caries have remained essentially unchanged for many years. Prescription strength or over-the-counter fluoride products are recommended for adults with high caries risk but have not been sufficient to reduce caries (Featherstone, 2008 ). An NIDCR consensus conference (Horowitz, 2004) emphasized the need to expand the evidence base for preventive agents for adults and suggested that chlorhexidine, an antimicrobial agent, merited further consideration. A 13-month trial in 240 45-to 75-year-old xerostomic individuals with high S. mutans counts tested the caries-preventive effects of 3 treatments: CHX dental coating (chlorhexidine diacetate 10% weight per volume [w/v] , Prevora ® ); a placebo coating (benzoin sumatra USP 20% [w/v]); and a sham coating (Banting et al., 2000) . CHX Technologies, Inc. (Toronto, ON, Canada) supplied all the coatings. In the intention-to-treat analysis, the active treatment group had 40.8% fewer root surfaces with caries (p ≤ 0.02) and 14.4% fewer coronal surfaces with caries (p ≤ 0.06) relative to the placebo coating group. No significant difference was seen versus the sham coating control group. This paper reports the primary findings of a trial testing the same agent in a larger, more diverse population of adults.
MAtErIAls & MEthODs
The Prevention of Adult Caries Study (PACS) was a multicenter, placebocontrolled, double blind, randomized clinical trial designed to test the hypothesis that a CHX coating, compared with a placebo coating, reduces dental caries increment in at-risk adults over a period of 13 mos. The study was conducted under an Investigational New Drug license from the US Food and Drug Administration (FDA).
The detailed study rationale and design are described elsewhere (Vollmer et al., 2010) . Summary details are provided here and in the Appendix. Four clinical centers provided a diverse sample with respect to fluoride exposure, dental reimbursement, and race: Delta Dental (Westborough, MA, USA);
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Kaiser Permanente Dental Program (Portland, OR, USA); Tuba City Regional Health Care Corporation (Navajo Nation in Arizona, USA); and Tufts University School of Dental Medicine (Boston, MA, USA). The study chair was at Tufts; Kaiser Permanente Center for Health Research in Portland, OR, served as the data coordinating center. The Institutional Review Board at each institution approved the study, all participants provided written informed consent, and all study personnel were trained and certified in Good Clinical Practice (Food and Drug Administration, 1996) .
study Population
Participants were from 18 to 80 yrs old and had 20 or more intact teeth and 2 or more lesions (at least 1 cavitated) at screening. We excluded participants for whom the study treatment was contraindicated or whose health might affect outcomes or ability to complete the study.
Sites used a variety of means to identify likely eligible individuals, who were then invited for a formal eligibility screening visit. Before participants were randomized, they received restorative care for all cavitated lesions from a dentist who was independent of the study. A second, baseline oral examination was obtained at the randomization visit, after which the initial treatment was applied. Of 1521 individuals attending an initial screening visit, 124 (8%) were ineligible, 983 (65%) were randomized, and the remainder either refused or were still pending at the close of recruitment ( Fig.) .
randomization and blinding
Participants and staff were blinded to study arm. A centralized Web-based application randomized participants 1:1 to receive CHX or its placebo. Randomization was stratified by clinical center and age tertiles with permuted blocks of various sizes within strata. Staff received a number corresponding to a sealed box containing the treatment vials for that participant. Active and placebo materials were packaged identically by an independent vendor, and were distinguishable only by a numeric label.
study treatments
Study treatments were applied by blinded and certified personnel after participants received a rubber cup prophylaxis with non-fluoridated paste and gross scaling as needed. The first 4 treatment applications occurred weekly in the first mo after randomization, followed by a fifth treatment 6 mos later. Cavitated lesions discovered at the fifth visit were restored before the coatings were applied. Participants received either the active coating (chlorhexidine diacetate 10% [w/v], Sumatra benzoin 20% [w/v], and alcohol, Prevora ® ) or the placebo coating (Sumatra benzoin 20% [w/v] and alcohol), followed by application of a methacrylate coating designed to protect the initial coating. CHX Technologies, Inc. (Toronto, ON, Canada) supplied all the coatings. Coatings were applied to all tooth surfaces, and staff weighed each vial before and after application to assess the applied dose. We did not attempt to assess whether material was left on the applicator or lost to evaporation. Although the active and placebo coatings had some differences in taste, this was not noticeable when the materials were applied according to protocol. A detailed rationale for the treatment protocol is included in the Appendix.
schedule and types of Measurements
Demographic information and predictors of caries were collected at initial screening. Medical history, oral health behaviors, and caries data were collected at randomization and again 7 and 13 mos post-randomization. Information about medical history changes, soft tissue changes, adverse events, medication usage, and acidic beverage consumption was collected at each visit. Adverse events were coded by certified coordinating center staff using the Medical Dictionary for Regulatory Activities (MedDRA Maintenance and Support Services Organization, 2005).
caries Examination
Paralleling previous trials of the same agent (Banting et al., 2000; Forgie et al., 2000) , we used the Pitts & Fyffe taxonomy (Pitts and Fyffe, 1988) , which identifies 3 stages of lesions on coronal surfaces: non-cavitated lesions (D 1 ); cavitation extending into, but not through, the enamel (D 2 ); and cavitated lesions that involve the dentin (D 3 ). The classification was extended to root surfaces with 2 stages: non-cavitated (D 1 ) and cavitated (D 2 ). Caries was judged visually (without radiographs) by trained, calibrated examiners using proper lighting, 5 sec of airdrying, and a CPITN probe. Examiners also noted missing teeth (M), unscorable surfaces (Y), and the presence of crowns (C) or fillings (F) on tooth surfaces; for example, a code of CD 1 denoted the presence of both a crown and a marginal D 1 lesion on a surface. Pit and fissure sealants were coded but treated as sound (S) surfaces in our analysis. We also treated D 2 and D 3 lesions equivalently and refer to them hereafter as simply D 2 lesions. Calls for all 32 possible teeth were recorded, and all teeth were judged to have 9 surfaces (5 coronal and 4 root), making a total of 288 surface calls.
Examiners received calibration training annually (Banting et al., 2011) . Unweighted kappa (Cohen, 1960) was used to estimate intra-and inter-examiner reliability of the 5×5 classification of sound vs. D 1 vs. D 2 vs. filled or crowned vs. missing or unscorable. Aggregating over calibration sessions and examiners, the mean intra-and inter-examiner reliabilities were 0.86 and 0.77 (see Appendix for more extensive calibration results).
Outcome Measures
The primary outcome (total net D1-2FS increment) was the sum of weighted counts of transitions in tooth surface status (root and coronal surfaces combined) from randomization to the 13-month follow-up visit. Disease progression had a positive weight (e.g., S-to-D 1 or D 1 -to-D 2 = 1, S-to-D 2 = 2). Reversal had a negative weight (e.g., D 1 -to-S = −1). No change, transitions to or from missing or unscorable, and impossible transitions had 0 weight. Incident fillings and crowns were treated the same as incident D 2 lesions for purposes of scoring.
Three secondary outcomes were examined: the cumulative net D 1-2 FS increment (which was similar to the total net D 1-2 FS increment but separately scored and combined transitions from the baseline to 7-month visit and from the 7-to 13-month visits), the total crude D 1-2 FS increment (analogous to the total net D 1-2 FS increment but ignoring reversals), and the cumulative crude D 1-2 FS increment (analogous to the cumulative net D 1-2 FS increment but ignoring reversals). All scores were rank-normalized and re-scaled to observed mean and variance over all participants (Banting et al., 2000) .
statistical Analysis
The primary outcome analysis (conducted with SAS® Release 9.2) was performed on the Intention-to-Treat sample (ITT) with standard linear regression, with treatment and site as class variables and age and age-squared as continuous covariates. A planned secondary analysis tested for a site-by-treatment interaction. Identical analyses were carried out in the per-protocol subsample (defined as participants receiving all 5 treatments and with data collected on a protocol-defined schedule) and for all 3 secondary outcomes in both samples. No interim analysis was conducted.
We used SAS® PROC MI to create 8 imputed datasets via data augmentation with Markov Chain Monte Carlo sampling (Schafer and Graham, 2002) . Identical analyses were run on each dataset, with results combined with SAS® PROC MIANALYZE to obtain p-values that were adjusted for the uncertainty inherent in imputing missing data (Rubin, 1987) . The statistician was blinded to treatment group in the 13-month data until after the imputations were completed and data were locked.
Sample size was estimated with simulated data with rank normalized scores. We calculated that 832 participants would yield a power of 90% to detect a 20% reduction in caries incidence (from a hypothesized mean increment of 1.5), and adopted a target of 1000 randomized participants to allow for attrition.
Participants who had one or more treatment applications were included in the safety analysis, which computed odds ratios and 90% confidence intervals for adverse events reported by 1% or more of the participants based on the MedDRA ® Preferred Term classification.
rEsults
The two study arms were well-matched by baseline characteristics (Table 1) . Follow-up and treatment adherence were excellent ( Fig.) . The mean dose of CHX over all applications in the ITT sample was 41 mg (95% CI = 40.1, 41.5 mg), with mean cumulative dose of 198.4 mg (95% CI = 194.7, 202.0 mg). The corresponding target doses were 33 mg/application and 165 mg cumulative.
The vast majority (94%) of "transitions" between the baseline and 13-month visits were no change (diagonals in Appendix Table  6 ). Ignoring the impossible transitions, which are not scored in the analysis, the mean number of cavitated, filled, or crowned tooth surfaces increased from 31.8 to 34.1 per participant over this timeframe, while the mean number of surfaces with uncavitated (D 1 ) lesions decreased from 7.1 to 4.2. Since 93% of root surfaces were not exposed, these represent primarily coronal data.
For the ITT sample, we failed to observe a significant difference in total net D 1-2 FS increment between the two treatment arms, with the observed increment actually higher for the active group (Table 2) . No significant site-by-treatment interaction was observed (p = 0.49), although there was a significant site main effect (p < 0.0001). Analyses of secondary outcomes for the ITT sample and of all 4 outcomes in the per-protocol sample produced qualitatively similar results (Table 3 ).
In the safety sample, the incidence of adverse events differed for only 2 events. Pharmaceutical product complaint (e.g., unpleasant taste) was higher in the active group (28 vs. 12 participants, OR = 2.4, 90% CI = 1.4, 4.3), while dyspepsia was reported more frequently among those in the placebo arm (9 vs. 2, OR = 0.2, 90% CI = 0.1, 0.8). To our knowledge, no one became unblinded as a result of the taste of the coatings.
Unplanned exploratory analysis of the net D 2 FS caries increment (i.e., treating D 1 lesions as sound) found no overall treatment effect (see Appendix).
DIscussIOn
The PACS study has numerous important strengths, including the randomized design, double-blind treatments, careful attention to quality control, excellent participant retention and protocol adherence, a large sample, and generalizability to populations with varied dental delivery systems, access to dental care, and levels of fluoride exposure.
Our negative findings might have several explanations. First, the 10% (w/v) CHX coating used in this study may not be efficacious for coronal caries prevention. Consistent with our results, Banting and co-workers (Banting et al., 2000) did not see a statistically significant effect on coronal caries for chlorhexidine vs. either the placebo-coating or sham control groups. Similarly, Forgie and colleagues (Forgie et al., 2000) found no greater effect of a chlorhexidine coating on D 1-2 increment than in a placebo control in a three-year study of 1240 adolescents, although adherence in that study was poor. Systematic reviews have also found the evidence for chlorhexidine to be weak, especially for coronal caries prevention and in patients who are not at very high risk of caries progression (James et al., 2010; Bekhuis, 2011; Slot et al., 2011) . Since PACS participants had very few exposed root surfaces, ours was a study of primarily coronal caries increment. Second, PACS included transitions to and from uncavitated (i.e., D 1 ) lesions in the primary outcome. We chose this outcome based on ICDAS reports and on assertions of sensitivity and efficiency of the D 1 outcome from other research (Kingman and Selwitz, 1997; Chesters et al., 2002; Biesbrock and Bartizek, 2005) . Nonetheless, we acknowledge that D 1 lesions are more difficult to detect than D 2 lesions, especially when they are located interproximally just under the contact.
Third, it may be that our follow-up period was too short for an effect to be observed, but this seems unlikely, given that the estimated overall treatment effect in this study, though essentially zero, was in the opposite direction from that predicted. Moreover, we had greater power than originally planned to detect a 20% drop in mean caries increment, since the observed caries increment in the placebo group was higher than assumed in our sample size calculations (2.4 vs. 1.5).
Other factors may also have contributed to our negative findings. Participants had all cavitated lesions restored at baseline and again midway through the study, and had a rubber cup prophylaxis and gross scaling as needed prior to each treatment application. These factors, together with the fact that a protective coating was applied at each treatment visit, may have reduced the cariogenic microflora in all participants (Axelsson et al., 2004) . Certainly the decrease in D 1 surfaces that occurred in participants in both treatment arms suggests that remineralization was achieved in both groups, though the lack of a prophy cleaning at the final examination could also have impaired visibility and thus contributed to an increase in missed D 1 calls at that visit. In addition, participants had varying use of fluoride products (including the fluoridated toothpaste provided by the study) and varying exposure to fluoridated community water. While this may have improved the generalizability of our findings, it may also have inflated the variance of our study outcomes. Finally, lack of radiographs (done at the request of the FDA) may have reduced the accuracy of the calls made during the oral examinations.
This trial of 10% CHX dental coating found no evidence of anti-caries effect on the net or crude D 1-2 FS increment. Based on these findings and the available literature, we conclude that chlorhexidine is not effective in preventing coronal caries. It may have a role in the prevention of root caries in very high-risk populations, although further studies would be needed to confirm this.
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